CA2306985A1 - Novel use of compounds for anti-pruritic activity - Google Patents

Novel use of compounds for anti-pruritic activity Download PDF

Info

Publication number
CA2306985A1
CA2306985A1 CA002306985A CA2306985A CA2306985A1 CA 2306985 A1 CA2306985 A1 CA 2306985A1 CA 002306985 A CA002306985 A CA 002306985A CA 2306985 A CA2306985 A CA 2306985A CA 2306985 A1 CA2306985 A1 CA 2306985A1
Authority
CA
Canada
Prior art keywords
xanthine
compound
cyclopropylmethyl
butyl
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306985A
Other languages
English (en)
French (fr)
Inventor
Siegfried Benjamin Christensen Iv
Don E. Griswold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2306985A1 publication Critical patent/CA2306985A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002306985A 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity Abandoned CA2306985A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17
US60/063,746 1997-10-17
PCT/US1998/021886 WO1999020280A1 (en) 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity

Publications (1)

Publication Number Publication Date
CA2306985A1 true CA2306985A1 (en) 1999-04-29

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002306985A Abandoned CA2306985A1 (en) 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity

Country Status (18)

Country Link
EP (1) EP1030666A4 (xx)
JP (1) JP2001520196A (xx)
KR (1) KR20010031149A (xx)
CN (1) CN1306426A (xx)
AR (1) AR015966A1 (xx)
AU (1) AU740875B2 (xx)
BR (1) BR9814080A (xx)
CA (1) CA2306985A1 (xx)
CO (1) CO4810374A1 (xx)
CZ (1) CZ20001376A3 (xx)
HU (1) HUP0003792A3 (xx)
IL (1) IL135581A0 (xx)
NO (1) NO20001847D0 (xx)
NZ (1) NZ503551A (xx)
PL (1) PL341062A1 (xx)
TR (1) TR200001040T2 (xx)
WO (1) WO1999020280A1 (xx)
ZA (1) ZA989450B (xx)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492543B2 (en) 2007-08-17 2013-07-23 Eisai R&D Management Co., Ltd. Method for producing quinazoline derivative
TWI404709B (zh) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
US8530654B2 (en) 2007-02-16 2013-09-10 Eisai R&D Management Co., Ltd. Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
CA2436535A1 (en) 2001-01-31 2002-08-08 Prizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
EE200300362A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid
HUP0302891A2 (hu) 2001-01-31 2003-12-29 Pfizer Products Inc. PDE4 izoenzimek inhibitoraiként alkalmazható éterszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
EP1647274A4 (en) * 2003-07-17 2008-12-10 Ono Pharmaceutical Co REMEDY AGAINST PRURIT COMPRISING A PIPERIDINE DERIVATIVE AS AN ACTIVE INGREDIENT
JP2005187458A (ja) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd シロミラストまたはその塩を有効成分とする掻痒治療剤
WO2005053672A1 (ja) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. シロミラストまたはその塩を有効成分とする掻痒治療剤
WO2005077950A2 (en) 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
JP2008137892A (ja) * 2005-03-04 2008-06-19 Eisai Co Ltd 止痒剤
BRPI0614270A2 (pt) 2005-08-10 2011-03-22 Smithkline Beecham Corp derivados xantina como seletivos agonistas de ha74a
EP1992622B1 (en) * 2006-02-21 2011-07-27 Eisai R&D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
US8513269B2 (en) 2007-08-17 2013-08-20 Eisai R&D Management Co., Ltd. Preparation for external use
US20140121240A1 (en) 2011-06-28 2014-05-01 Maruho Co., Ltd. Novel pharmaceutical composition
EA034139B1 (ru) 2015-01-30 2020-01-09 Шаньтонь Фарма Ко., Лтд. Профилактика или лечение мочекислых или подагрических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563168B1 (en) * 1990-12-21 2000-07-05 Beecham Group Plc Xanthine derivatives
ATE224386T1 (de) * 1996-03-26 2002-10-15 Altana Pharma Ag Neue in 6-position substituierte phenanthridine
ES2187775T3 (es) * 1996-05-15 2003-06-16 Altana Pharma Ag Imidazopiridinas.
DE69817548T2 (de) * 1997-03-07 2004-06-17 Altana Pharma Ag Tetrazole derivate
PL336464A1 (en) * 1997-03-18 2000-06-19 Basf Ag Method of and compositions for modulating reactivity in respect to corticosteroids i
WO1998055481A1 (en) * 1997-06-03 1998-12-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404709B (zh) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
US8530654B2 (en) 2007-02-16 2013-09-10 Eisai R&D Management Co., Ltd. Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
US8492543B2 (en) 2007-08-17 2013-07-23 Eisai R&D Management Co., Ltd. Method for producing quinazoline derivative

Also Published As

Publication number Publication date
IL135581A0 (en) 2001-05-20
ZA989450B (en) 1999-04-19
AU740875B2 (en) 2001-11-15
TR200001040T2 (tr) 2001-01-22
KR20010031149A (ko) 2001-04-16
AU1093899A (en) 1999-05-10
WO1999020280A1 (en) 1999-04-29
CZ20001376A3 (cs) 2002-06-12
NZ503551A (en) 2002-05-31
CN1306426A (zh) 2001-08-01
HUP0003792A3 (en) 2001-12-28
EP1030666A4 (en) 2002-10-16
BR9814080A (pt) 2000-09-26
HUP0003792A2 (hu) 2001-10-28
CO4810374A1 (es) 1999-06-30
NO20001847L (no) 2000-04-10
NO20001847D0 (no) 2000-04-10
AR015966A1 (es) 2001-05-30
EP1030666A1 (en) 2000-08-30
PL341062A1 (en) 2001-03-26
JP2001520196A (ja) 2001-10-30

Similar Documents

Publication Publication Date Title
AU740875B2 (en) Novel use of compounds for anti-pruritic activity
Golightly et al. Pharmaceutical excipients: adverse effects associated with inactive ingredients in drug products (Part I)
JPS62249923A (ja) パ−キンソン病、うつ病、ナルコレプシ−および脳器官精神症候群の抑制用薬剤およびその製造方法
JP2002527392A (ja) 末梢的に作用する抗掻痒アヘン剤
ITMI20080395A1 (it) Formulazioni per il trattamento delle verruche e delle placche psoriatiche
JPWO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
WO2008091704A2 (en) Treatment of cushing's syndrome and autism
JPS62185014A (ja) 複合調剤薬
US20030050329A1 (en) Synergistic combination comprising roflumilast and a PDE-3 inhibitor
JPH02160720A (ja) 医薬組成物
JPH03204815A (ja) 皮膚炎に対する治療用組成物
WO1999026613A1 (en) Aminoguanidine compositions for treating skin proliferative diseases
JP2016517419A (ja) 障害組織の全身および局所組合わせ処置
WO1989010143A1 (en) Certain paf antagonist antihistamine combinations and methods
UA123780C2 (uk) Лікування екземи кистей
MXPA00003775A (en) Novel use of compounds for anti-pruritic activity
JPH03215435A (ja) アルドース還元酵素阻害剤を主成分とする潰瘍治療剤
JPH06500129A (ja) ヌクレオシド誘導体
JPS6245525A (ja) 脂質低下剤
US20060079513A1 (en) Methods and compositions including methscopolamine nitrate
RU2426540C1 (ru) Противовоспалительное и противоаллергическое лекарственное средство и фармацевтическая композиция на его основе
JP2503985B2 (ja) 催眠鎮静剤
EP0338010B1 (en) Pharmaceutical compositions for treatment of hyperproliferate skin disease
AU1563902A (en) Novel use of compounds for anti-pruritic activity
JPH0522687B2 (xx)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued